HONG KONG – Biotech and medtech companies operating in China now have to pay more attention to the cost of regulatory approvals after the national regulator drastically raised registration application fees for both clinical trials and marketing approvals.
HONG KONG – In a move that sent its stock down more than 3 percent Tuesday, Hong Kong-listed Chinese pharmaceutical company Luye Pharma Group (HK:2186) terminated a billion-dollar acquisition deal.
HONG KONG – In a move that sent its stock down more than 3 percent Tuesday, Hong Kong-listed Chinese pharmaceutical company Luye Pharma Group (HK:2186) terminated a billion-dollar acquisition deal.
HONG KONG – Biotech and medtech companies operating in China now have to pay more attention to the cost of regulatory approvals after the national regulator drastically raised registration application fees for both clinical trials and marketing approvals.
HONG KONG – Following the National Development and Reform Commission (NDRC)’s notice on removing the government price cap on most of the drugs in China, the government is slowly but gradually loosening its grip on drug prices. Large domestic pharmaceutical firms are most likely to benefit from that deregulation.
HONG KONG – After eyeing biopharmaceuticals as a key area for breakthrough developments, China’s State Council has released a roadmap for the manufacturing sector.
HONG KONG – Not only is China’s biotech sector growing fast, but it is also changing rapidly. And those changes in its basic structure are appealing to Asia-focused biotech investors who gathered this week at Asia Biotech Invest 2015.
